Skip to content
2000
Volume 24, Issue 14
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Introduction: In this study, a series of novel piperazine derivatives were synthesised with high-to-good yields, and their structural analogies were confirmed using FTIR, 1H-NMR, and LC-MS techniques. Methods: The synthesised compounds were evaluated for antioxidant and antimicrobial activities. Among the four synthesised piperazine derivatives, compound PD-2 exhibited relatively good antioxidant activity, with an IC value of 2.396 μg/mL, while the other three derivatives showed moderate to low antioxidant activity. Furthermore, compound PD-2 displayed antimicrobial activity against , a gram-negative bacterium, and , a fungus. However, all four compounds showed strong resistance against grampositive bacteria, . Results: Additionally, compound PD-1 exhibited significant antihistamine activity, eliciting an 18.22% reduction in histamine levels. Both PD-1 and PD-2 demonstrated noteworthy anti-inflammatory activity in a dosedependent manner (5-10 μM), leading to the inhibition of nitrite production up to 39.42% and 33.7% at higher concentrations (10 μM) and inhibition of tumour necrosis factor-alpha (TNF-α) generation up to 56.97% and 44.73% at 10 μM, respectively. Additionally, both novel molecules PD-1 and PD-2 effectively restrained the growth of HepG2 cells in a manner that is dependent on the dosage up to 55.44% and 90.45% at the highest concentrations (100 μg/mL), respectively. Conclusion: These findings substantiate the rationale for further investigation into the novel series of persuasive piperazine analogues as potential agents with anti-inflammatory, antihistamine and anticancer properties.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206295673240409071016
2024-08-01
2025-04-22
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/0118715206295673240409071016
Loading

  • Article Type:
    Research Article
Keyword(s): antimicrobial; cytokine ELISA; DPPH; HepG2 cells; Piperazine scaffold; ZOI
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test